Singapore markets closed
Straits Times Index
3,173.93 +34.17 (+1.09%) S&P 500
3,951.57 +34.93 (+0.89%) Dow
32,244.58 +382.60 (+1.20%) Nasdaq
11,675.54 +45.02 (+0.39%) Bitcoin USD
28,137.58 -146.50 (-0.52%) CMC Crypto 200
611.89 +12.22 (+2.04%)
Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 38.53 |
| Open | 38.48 |
| Bid | 35.00 x 900 |
| Ask | 44.23 x 800 |
| Day's range | 38.01 - 39.12 |
| 52-week range | 33.36 - 85.53 |
| Volume | |
| Avg. volume | 597,437 |
| Market cap | 2.738B |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.59 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 91.56 |
- Zacks
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
- Zacks
Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others
Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.
- Zacks
Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
© 2023 Yahoo. All rights reserved.
